Insight Molecular Diagnostics Enrolls First Several Patients In Its GALACTIC Study Evaluating GraftAssure Molecular Test For Monitoring Rejection In Kidney Transplant Recipients

Benzinga · 1d ago

This study serves to introduce GraftAssure technology to new transplant centers and additionally builds validation data ahead of potential FDA authorization of GraftAssureDx, a kitted version of the company’s clinical assay.

iMDx seeks to deliver a best-in-class molecular diagnostic test kit, to expand and improve testing access for kidney transplant patients, which it anticipates will deliver new value in the estimated $3 billion addressable market for regulated transplant rejection testing.